Mitsubishi UFJ Asset Management Co. Ltd. Has $390.47 Million Stock Position in Abbott Laboratories $ABT

Mitsubishi UFJ Asset Management Co. Ltd. cut its holdings in Abbott Laboratories (NYSE:ABT) by 12.4% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 4,303,186 shares of the healthcare product maker’s stock after selling 610,882 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned approximately 0.25% of Abbott Laboratories worth $390,471,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Freemont Management S.A. raised its holdings in Abbott Laboratories by 197.2% in the 4th quarter. Freemont Management S.A. now owns 10,700 shares of the healthcare product maker’s stock valued at $1,341,000 after acquiring an additional 7,100 shares in the last quarter. PFA Pension Forsikringsaktieselskab bought a new position in shares of Abbott Laboratories in the fourth quarter worth $116,580,000. Thrivent Financial for Lutherans raised its stake in Abbott Laboratories by 24.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 246,586 shares of the healthcare product maker’s stock valued at $30,931,000 after purchasing an additional 48,286 shares in the last quarter. Aureus Asset Management LLC lifted its position in Abbott Laboratories by 25.0% during the first quarter. Aureus Asset Management LLC now owns 331,920 shares of the healthcare product maker’s stock worth $34,078,000 after purchasing an additional 66,422 shares during the period. Finally, North Dakota State Investment Board acquired a new stake in Abbott Laboratories during the fourth quarter worth about $7,439,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: The FDA authorized Abbott’s Libre Duo 10 Day, the first U.S. wearable designed to continuously monitor both glucose and ketones. The device is cleared for diabetes patients age two and older and could strengthen Abbott’s Libre franchise, particularly as the company works toward integration with insulin pumps. What Does Abbott Laboratories FDA Clearance Mean for Its Diabetes Device Push?
• Positive Sentiment: Abbott received the European CE Mark for its next-generation Amulet 360 left atrial appendage occluder. The device is intended to reduce stroke risk in patients with non-valvular atrial fibrillation and may reduce reliance on blood-thinning medication. Recent trial data reportedly met safety and effectiveness benchmarks, supporting Abbott’s structural-heart and electrophysiology businesses. Abbott Amulet 360 Receives CE Mark
• Positive Sentiment: TD Cowen analyst commentary indicated that Abbott’s stock could rise, providing an additional vote of confidence in the company’s outlook. TD Cowen Says Abbott Stock Could Rise
• Neutral Sentiment: The regulatory approvals are strategically important, but their financial benefits will depend on commercial adoption, reimbursement, competitive responses and the timing of integration with insulin-pump systems.
• Negative Sentiment: Abbott underperformed while the broader market gained. The pullback suggests that investors may be focusing on the stock’s relatively high valuation and the fact that the newly approved products are longer-term growth catalysts rather than immediate earnings drivers. Why Abbott Stock Declined as the Market Gained

Abbott Laboratories Price Performance

ABT stock opened at $111.46 on Friday. The stock has a market cap of $192.87 billion, a price-to-earnings ratio of 36.07, a P/E/G ratio of 2.21 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The company has a 50 day simple moving average of $102.12 and a 200 day simple moving average of $100.13. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion for the quarter, compared to analysts’ expectations of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s revenue was up 13.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Research analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th were given a $0.63 dividend. The ex-dividend date was Wednesday, July 15th. This represents a $2.52 annualized dividend and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 81.55%.

Analyst Ratings Changes

Several brokerages have recently commented on ABT. Weiss Ratings upgraded shares of Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, August 6th. Robert W. Baird started coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price objective on the stock. Wells Fargo & Company upped their target price on Abbott Laboratories from $109.00 to $112.00 and gave the stock an “overweight” rating in a research note on Friday, July 17th. JPMorgan Chase & Co. raised their target price on Abbott Laboratories from $110.00 to $120.00 and gave the company an “overweight” rating in a report on Friday, July 17th. Finally, Citigroup lifted their price target on Abbott Laboratories from $108.00 to $112.00 and gave the company a “buy” rating in a research note on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $119.50.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.